The vaccines are tailor-made to target each patient's unique cancer.
  • Zirconium@lemmy.worldEnglish
    80·
    13 days ago

    Marjorie Green, a senior vice president at Merck, called the five-year follow-up data a “meaningful milestone” and “encouraging.”

    Unfortunate name